News Release 

HIV prevention drug can curb the epidemic for high-risk groups in India

Making pre-exposure prophylaxis available in India would be a cost-effective way to reduce the spread of HIV and increase survival

Massachusetts General Hospital

Pre-exposure prophylaxis (PrEP), a combination drug used to prevent HIV infection, has already gained significant traction in the U.S. and Europe. The once-a-day pill, when taken consistently, can reduce the risk of HIV acquisition by over 85 percent. A new study published in Clinical Infectious Diseases by an international research team suggests that making PrEP available to men who have sex with men (MSM) and people who inject drugs (PWID) in India may be a cost-effective way of curbing the epidemic there.

"We know PrEP helps stop the spread of infection; the question is whether it is a good use of limited resources? Our study shows that PrEP is a cost-effective strategy for both MSM and PWID in India. For these groups, especially in areas with high HIV incidence, PrEP is worth rolling out," says lead and corresponding author Pooyan Kazemian, PhD, of the Massachusetts General Hospital (MGH) Medical Practice Evaluation Center, an instructor in Medicine at Harvard Medical School.

Using a widely-published mathematical model to project clinical and economic outcomes of HIV disease, the authors compared various prevention and testing programs - including annual or biannual HIV testing alone, as well as PrEP paired with HIV testing - that could help reduce HIV infection and therefore improve survival for these high-risk groups. Their findings suggest that PrEP would increase survival substantially by reducing infection risk, while more frequent HIV testing would provide little additional benefit. PrEP paired with biannual HIV testing was the only cost-effective strategy, improving average per-person survival by nearly one year and preventing more than 270,000 HIV transmissions in India over 15 years.

"While the World Health Organization recommends quarterly HIV testing for those on PrEP, our analysis identifies PrEP with semi-annual testing as the cost-effective HIV prevention strategy for MSM and PWID in India," says co-author Nagalingeswaran Kumarasamy, MBBS, PhD, of the CART Clinical Research Site, Infectious Diseases Medical Centre, Voluntary Health Services in Chennai, India.

However, the authors note, a nationwide PrEP rollout would be quite costly. If nearly 60 percent of MSM and PWID across India participated in the program, it would increase HIV care expenditures by over 900 million U.S. dollars over a 5-year period. "Our findings suggest that geographic areas of highest HIV incidence should be targeted first to reduce the budget required," says co-author Nomita Chandhiok, MBBS, DGO, PhD, of the Indian Council of Medical Research in New Delhi.

###

Additional co-authors of the study are senior author Kenneth A. Freedberg MD, MSc, and Sydney Costantini and Rochelle P. Walensky, MD, MPH, MGH Medical Practice Evaluation Center; A. David Paltiel, PhD, MBA, Yale School of Public Health; and Kenneth H. Mayer, MD, Beth Israel Deaconess Medical Center and the Fenway Institute. The study was supported by National Institute of Allergy and Infectious Diseases grants R01 MH10520, DA015612, R37 AI093269, 5UM1 AI069432, and R37 AI058736; the Harvard University Center for AIDS Research grant P30 AI060354, and by the Steve and Deborah Gorlin MGH Research Scholar Award.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $925 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2017 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.